Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Pain. 2017 Dec;158(12):2431–2441. doi: 10.1097/j.pain.0000000000001050

Table 2.

Summary of Opioid Agonist-mGluR5 Antagonist Interactions

Probe Drug, Intrathecal Opioid Agonist
ED50 value (C.I) nmol per 5 µL
mGluR5 antagonist
ED50 value (C.I) nmol/ 5 µL
Interaction
Oxymorphone + MPEP 1:2 Dose Ratio
Single Drug 3.0 (1.8–4.1) 5.3 (3.0–7.6)
Observed Combination 0.36 (0.18–0.54)* 0.72 (0.37–1.1)* Synergistic
Theoretical Additive 1.4 (0.99–1.8) 2.8 (2.0–3.6)
Oxymorphamine + MPEP 1:1 Dose Ratio
Single Drug 2.2 (1.4–3.0) 3.1 (2.2–4.0)
Observed Combination 0.43 (0.26–0.60)* 0.43 (0.26–0.60)* Synergistic
Theoretical Additive 1.3 (1.0–1.6) 1.3 (1.0–1.6)
*

Significant difference from theoretical additive by Student t test, p < 0.05